ClinicalTrials.gov
ClinicalTrials.gov Menu

Study of Nifurtimox to Treat Refractory or Relapsed Neuroblastoma or Medulloblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00601003
Recruitment Status : Recruiting
First Posted : January 25, 2008
Last Update Posted : April 26, 2017
Sponsor:
Collaborator:
Bayer
Information provided by (Responsible Party):
Giselle Sholler, Spectrum Health Hospitals

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : December 2018
  Estimated Study Completion Date : December 2020